Bank of America
GYRE icon

Bank of America’s Gyre Therapeutics GYRE Stock Holding History

Bank of America’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.5K Buy
10,538
+779
+8% +$6.05K ﹤0.01% 5559
2025
Q4 		$68.9K Buy
9,759
+3,072
+46% +$23.7K ﹤0.01% 5732
2025
Q3 		$49.9K Buy
6,687
+410
+7% +$3.11K ﹤0.01% 6835
2025
Q2 		$46.1K Buy
6,277
+1,402
+29% +$12.2K ﹤0.01% 6841
2025
Q1 		$37.6K Sell
4,875
-2,062
-30% -$22.6K ﹤0.01% 6815
2024
Q4 		$83.9K Buy
6,937
+1,996
+40% +$25.6K ﹤0.01% 6468
2024
Q3 		$62K Sell
4,941
-28
-0.6% -$361 ﹤0.01% 6488
2024
Q2 		$59.3K Buy
+4,969
New +$68.2K ﹤0.01% 6468
2023
Q4 		– Sell
-1,499
Closed -$10.8K – 8079
2023
Q3 		$10.8K Sell
1,499
-1,732
-54% -$11.6K ﹤0.01% 6843
2023
Q2 		$17K Buy
3,231
+1,090
+51% +$3.91K ﹤0.01% 6746
2023
Q1 		$6.65K Sell
2,141
-866
-29% -$3.29K ﹤0.01% 7007
2022
Q4 		$11.9K Buy
3,007
+9
+0.3% +$37 ﹤0.01% 6877
2022
Q3 		$11K Hold
2,998
– – ﹤0.01% 7206
2022
Q2 		$40K Sell
2,998
-297
-9% -$1.97K ﹤0.01% 6935
2022
Q1 		$16K Sell
3,295
-50
-1% -$248 ﹤0.01% 7606
2021
Q4 		$23K Sell
3,345
-116
-3% -$1.98K ﹤0.01% 7474
2021
Q3 		$107K Sell
3,461
-672
-16% -$22.1K ﹤0.01% 6683
2021
Q2 		$134K Sell
4,133
-3,948
-49% -$135K ﹤0.01% 6340
2021
Q1 		$306K Buy
8,081
+4,470
+124% +$204K ﹤0.01% 5733
2020
Q4 		$171K Sell
3,611
-10
-0.3% -$433 ﹤0.01% 5695
2020
Q3 		$116K Buy
3,621
+1,060
+41% +$41.5K ﹤0.01% 5612
2020
Q2 		$112K Sell
2,561
-746
-23% -$35K ﹤0.01% 5618
2020
Q1 		$108K Buy
3,307
+3,304
+110,133% +$152K ﹤0.01% 5484
2019
Q4 		$0 Sell
3
-12
-80% -$503 ﹤0.01% 7205
2019
Q3 		$0 Sell
15
-1,371
-99% -$73.9K ﹤0.01% 7342
2019
Q2 		$77K Sell
1,386
-23,555
-94% -$1.47M ﹤0.01% 6116
2019
Q1 		$1.52M Buy
24,941
+17,133
+219% +$1.1M ﹤0.01% 4205
2018
Q4 		$462K Buy
7,808
+7,172
+1,128% +$529K ﹤0.01% 4987
2018
Q3 		$52K Buy
636
+175
+38% +$13.9K ﹤0.01% 6197
2018
Q2 		$41K Buy
461
+155
+51% +$27.2K ﹤0.01% 6232
2018
Q1 		$59K Buy
306
+302
+7,550% +$56.3K ﹤0.01% 5971
2017
Q4 		$0 Hold
4
– – ﹤0.01% 7109
2017
Q3 		$0 Hold
4
– – ﹤0.01% 7136
2017
Q2 		$0 Hold
4
– – ﹤0.01% 7026
2017
Q1 		$0 Sell
4
-1
-20% -$58 ﹤0.01% 7075
2016
Q4 		$0 Sell
5
-9
-64% -$809 ﹤0.01% 7141
2016
Q3 		$2K Buy
+14
New +$2.11K ﹤0.01% 6822
2016
Q2 		– Hold
0
– – – 7207
2016
Q1 		– Hold
0
– – – 7118
2015
Q4 		– Sell
-48
Closed -$18.9K – 7351
2015
Q3 		$26K Sell
48
-2
-4% -$3.05K ﹤0.01% 6223
2015
Q2 		$110K Buy
50
+3
+6% +$6.01K ﹤0.01% 5539
2015
Q1 		$110K Hold
47
– – ﹤0.01% 5261
2014
Q4 		$97K Hold
47
– – ﹤0.01% 5904
2014
Q3 		$94K Sell
47
-72
-61% -$178K ﹤0.01% 6055
2014
Q2 		$422K Buy
+119
New +$388K ﹤0.01% 4784
2014
Q1 		– Sell
-10
Closed -$37K – 7626
2013
Q4 		$33K Sell
10
-2
-17% -$7.88K ﹤0.01% 6804
2013
Q3 		$51K Sell
12
-4
-25% -$16.1K ﹤0.01% 6414
2013
Q2 		$53K Buy
+16
New +$60.9K ﹤0.01% 6529

Other funds holding GYRE

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America's GYRE Position: Q1 2026 in Review

Bank of America increased its Gyre Therapeutics (GYRE) stake by 8% in Q1 2026, buying an estimated $6.05K and bringing the position to 10,538 shares worth $73.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5559.

Bank of America first reported a position in GYRE in Q2 2013 and has held it in 46 quarters since. The position peaked at $1.52M in Q1 2019. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

  • Bank of America held 10,538 shares of Gyre Therapeutics worth $73.5K as of Q1 2026.
  • Bank of America bought 779 Gyre Therapeutics shares in Q1 2026, an estimated $6.05K.
  • Gyre Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5559 holding.
  • Bank of America first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 46 quarters since.
  • Bank of America's Gyre Therapeutics position peaked at $1.52M in Q1 2019.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.